A subset of lung tumors is exquisitely sensitive to a class of recently approved anti-cancer drugs. Researchers at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna and the Ludwig Institute for Cancer Research in Oxford published this finding in the journal Nature Communications. It opens the way for new clinical trials in a type of cancer considered to be “undruggable” and may lead to a therapy for up to 10% of lung cancer patients. About 10% of lung tumors carry mutations in a gene called ATM. However, there are no drugs currently available to treat ATM mutant lung cancer.
Read the article: https://eurekalert.org/pub_releases/2016-12/crcf-nao120516.php